India and China are the new pharmaceutical research and development(R&D)hubs,with India having an edge in the race,according to a industry study sponsored by US-based Ewing Marion Kauffman Foundation.The study said that India was more mature in chemistry and drug-discovery activities than China.Chinese firms were more prevalent in less lucrative segments such as pre-clinical testing,animal experimentation and manufacturing.
展开▼
机译：根据美国尤因·马里昂·考夫曼基金会（Ewing Marion Kauffman Foundation）赞助的一项行业研究，印度和中国是新兴的药物研发中心，印度在竞争中占优势。中国公司在临床前测试，动物实验和制造等利润较低的领域中更为普遍。
展开▼
